Short-term exposure to L-type calcium channel blocker, verapamil, alters the expression pattern of calcium-binding proteins in the brain of goldfish, Carassius auratus

2015 ◽  
Vol 176-177 ◽  
pp. 31-43 ◽  
Author(s):  
Nikhil V. Palande ◽  
Rahul C. Bhoyar ◽  
Saikat P. Biswas ◽  
Arun G. Jadhao
Keyword(s):  
Calcium Channel ◽  
Expression Pattern ◽  
Calcium Channel Blocker ◽  
Calcium Binding ◽  
Carassius Auratus ◽  
Channel Blocker ◽  
Short Term ◽  
Goldfish Carassius Auratus ◽  
Short Term Exposure ◽  
The Brain

scholarly journals The Immunoreactivity of Calbindin on Cerebellum Cortex and Hippocampus of Mice Brain After One Week Exposure To Radiofrequency Radiation.

2017 ◽  
Vol 13 (3) ◽  
pp. 340-344
Author(s):  
Bijay Aryal
Keyword(s):  
Calcium Homeostasis ◽  
Calcium Binding ◽  
Behavior Changes ◽  
Short Term ◽  
Radiofrequency Radiation ◽  
Short Term Exposure ◽  
Mice Brain ◽  
Calcium Permeability ◽  
Calbindin D ◽  
The Brain

Background & Objectives:Radiofrequency radiation affects the calcium permeability and accordingly this induces pathophysiological changes in the brain and its subsequent output in the brain as tumor genesis, neural degeneration, and cognition or behavior changes. Hence, we investigated the effects of radiofrequency (RF) radiation on calcium binding proteins, reactive gliosis, and tumor genesis in mouse brain. Materials & Methods:Mice were exposed to radiofrequency radiation in the cage chamber with average specific absorption rate (SAR) of 1.6 W/kg and 4.0 W/Kg for one hour per day for five days. For histochemical studies, radiofrequency exposed brains were compared with sham control using calbindin D-28k antibody.Results:The immunoreactivity of calbindin D-28k, a marker for calcium homeostasis was found to increase in dose-response manner in hippocampus and cerebellar cortex.Conclusion:The short-term exposure to 835 MHz RF could induce disruption of calcium homeostasis and resulting neurobehavioral changes or brain tumor. 

scholarly journals Association Between Prior Calcium Channel Blocker Use and Mortality in Septic Patients: A Meta-Analysis of Cohort Studies

2021 ◽  
Vol 12 ◽  
Author(s):  
Xianfei Ding ◽  
Yuqing Cui ◽  
Huoyan Liang ◽  
Dong Wang ◽  
Lifeng Li ◽  
...  
Keyword(s):  
Septic Shock ◽  
Cohort Studies ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Secondary Outcome ◽  
Short Term ◽  
Short Term Mortality

Background: The aim of this study was to comprehensively review the literature and synthesize the evidence concerning the relationship between prior calcium channel blocker (CCB) use and mortality in patients with sepsis.Methods: The Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (EMBASE), Cochrane CENTRAL, and Web of Science databases were searched from their inception to April 9, 2020. Cohort studies related to prior calcium channel blocker use in patients with sepsis were analyzed. Pairs of reviewers independently screened the studies, extracted the data, and assessed the risk of bias. The primary outcome of 90-days mortality or secondary outcome of short-term mortality, including 30-days, Intensive Care Unit (ICU), and in-hospital mortality, were analyzed. Heterogeneity among studies was assessed using the I2 statistic and was considered moderate if I2 was 50–75% and high if I2 was ≥75%. Random-effects models were used to calculate the pooled odds ratios (ORs) and 95% confidence intervals (CIs). The quality of the studies was evaluated with the Newcastle-Ottawa Scale (NOS). Sensitivity analyses were performed to examine the robustness of the results.Results: In total, 639 potentially relevant studies were identified, and the full texts of 25 articles were reviewed. Ultimately, five cohort studies involving 280,982 patients were confirmed to have a low risk of bias and were included. Prior CCB use was associated with a significantly lower 90-days mortality in sepsis patients [OR, 0.90 (0.85–0.95); I2 = 31.9%]. Moreover, prior CCB use was associated with a significantly reduced short-term mortality rate in septic shock patients [OR, 0.61 (0.38–0.97); I2 = 62.4%] but not in sepsis patients [OR, 0.83 (0.66–1.04); I2 = 95.4%].Conclusion: This meta-analysis suggests that prior CCB use is significantly associated with improved 90-days mortality in sepsis patients and short-term mortality in septic shock patients. This study provides preliminary evidence of an association between prior CCB use and mortality in sepsis patients.

Conventional and Unconventional Lifesaving Therapies in an Adolescent With Amlodipine Ingestion

2016 ◽  
Vol 36 (4) ◽  
pp. 64-69 ◽  
Author(s):  
Karin E. Reuter-Rice ◽  
Bradley M. Peterson
Keyword(s):  
Critical Care ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Short Term ◽  
Care Nurse ◽  
Severe Hypotension ◽  
Treatment Of Hypertension ◽  
Dihydropyridine Calcium Channel Blocker ◽  
Life Threatening

Amlodipine, a dihydropyridine calcium channel blocker, is commonly prescribed for the treatment of hypertension. Ingestion of an overdose leads to severe hypotension; if the hypotension is not treated, death may be imminent. Conventional and unconventional interventions were used to treat an adolescent who ingested a life-threatening dose of amlodipine. Severe hypotension resistant to conventional treatment with intralipids and hyperinsulinemia-euglycemia therapy led to the use of plasmapheresis and a pneumatic antishock garment as lifesaving measures. Plasmapheresis has been described in only one other case of severe amlodipine overdose, and the use of a pneumatic antishock garment has never been described in the management of a calcium channel blocker overdose. Because short-term use of a pneumatic antishock garment has associated risks, the critical care nurse’s anticipation of side effects and promotion of safe use of the garment were instrumental in the patient’s care and outcome. (Critical Care Nurse. 2016; 36[4]:64–69)

scholarly journals Changes In Liver and Brain Cytochrome P450 after Multiple Cocaine Administration, Alone and in Combination with Nifedipine

2007 ◽  
Vol 58 (3) ◽  
pp. 287-291 ◽  
Author(s):  
Vessela Vitcheva ◽  
Mitka Mitcheva
Keyword(s):  
Cytochrome P450 ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Wistar Rats ◽  
Channel Blocker ◽  
Cocaine Administration ◽  
Multiple Administration ◽  
Brain Microsomes ◽  
Male Wistar Rats ◽  
The Brain

Changes In Liver and Brain Cytochrome P450 after Multiple Cocaine Administration, Alone and in Combination with NifedipineThe objective of this study was to evaluate possible changes caused by multiple cocaine administration, alone and in combination with 1,4-dihydropiridine calcium channel blocker nifedipine, on cytochrome P450 levels both in the brain and liver. The experiment was done on male Wistar rats divided in four groups: control, treated with nifedipine (5 mg kg-1 i.p. for five days), treated with cocaine (15 mg kg-1 i.p. for five days), and treated with nifedipine and 30 minutes later with cocaine (also for five days). Total cytochrome P450 was measured spectrometrically in liver and brain microsomes. Multiple administration of cocaine alone and in combination with nifedipine did not change the brain P450 significantly. In the liver, nifedipine significantly increased P450 by 28 % vs. control. In contrast, cocaine significantly decreased P450 by 17 % vs. control. In animals treated with nifedipine and cocaine, cytochrome P450 increased 11 % (p<0.01) vs. control, decreased 12.5 % (p<0.001) vs. nifedipine group and increased 34 % (p<0.0001) vs. cocaine group. These results suggest that the cocaine and nifedipine interact at the metabolic level.

Isradipine—Another Calcium-Channel Blocker for the Treatment of Hypertension and Angina

1992 ◽  
Vol 26 (6) ◽  
pp. 789-799 ◽  
Author(s):  
Larry M. Lopez ◽  
Tamara M. Santiago
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
English Language ◽  
Channel Blocker ◽  
Data Extraction ◽  
Pharmacokinetic Parameters ◽  
Channel Blockers ◽  
Short Term ◽  
Extensive Experience ◽  
Medline Search

OBJECTIVE: To review the pharmacology, pharmacokinetic disposition, dose recommendations, adverse effects, drug interactions, and efficacy of isradipine in patients with hypertension or ischemic heart disease. DATA SOURCES: Data from scientific literature were extracted, evaluated, and summarized for presentation. A MEDLINE search was conducted using the following indexing terms: isradipine, calcium-channel blockers, hypertension, and angina pectoris. Experiences from studies evaluating isradipine reported in the form of articles, abstracts, or proceedings involving patients or healthy subjects were considered for inclusion. STUDY SELECTION: Special consideration was given to clinical studies that had been designed in a blind, randomized fashion. Studies that compared the effectiveness and safety of isradipine with another antihypertensive or antianginal agent or placebo were included. DATA EXTRACTION: Data from human studies published in the English language were evaluated. Trials were evaluated according to sample size, design, and adequacy of description of therapeutic response. DATA SYNTHESIS: Isradipine is a new dihydropyridine calcium-channel blocker that appears to exert less negative inotropic activity than nifedipine and to selectively inhibit sinoatrial conduction. Pharmacokinetic parameters are quite variable and considerably more work is needed to better describe the kinetic disposition of isradipine. Antihypertensive efficacy has been demonstrated extensively in a number of short-term trials. Antianginal efficacy also has been observed in a few short-term trials and is comparable to that of isosorbide dinitrate and nifedipine. Extensive experience with isradipine is minimal and no clear-cut advantages over existing compounds have been noted thus far. CONCLUSIONS: The place of isradipine in the therapy of hypertension and myocardial ischemia is unclear and its routine use cannot yet be recommended based solely on clinical grounds.

Sign in / Sign up

Export Citation Format

Share Document